{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:44:52Z","timestamp":1777481092826,"version":"3.51.4"},"reference-count":43,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Optimize the treatment of extensive-stage small cell lung cancer (ES-SCLC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>We collected data on patients with ES-SCLC who had stable disease (SD) after two cycles of first-line chemotherapy combined with immunotherapy (CIO) and subsequently received tailored treatment with anlotinib. The primary endpoints of the study were progression-free survival and overall survival (OS), while secondary endpoints included overall response rate (ORR), disease control rate (DCR), and adverse events (AEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 45 patients were ultimately enrolled in the study. Preliminary analysis indicated that the integration of anlotinib provides promising efficacy for patients with ES-SCLC who had SD after two cycles of CIO. ORR and DCR were 26.67% and 62.22%, respectively, with median progression-free survival and median OS were 6.0 months and 10.0 months. Furthermore, subgroup analysis results showed that patients who experienced hypertension, proteinuria, and hand-foot syndrome during treatment had better efficacy. In addition, mechanistic analysis suggested that this regimen may activate the immune system by depleting immune suppression, thereby exerting a synergistic antitumor effect. Beyond the promising efficacy, the overall AEs of this regimen were manageable, indicating a potential positive outlook for this treatment model in this patient population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The adaptive treatment with anlotinib can significantly improve outcomes for these patients, with manageable toxicities, suggesting that this treatment model has the potential to become an important option for first-line therapy in ES-SCLC. However, its true clinical value requires further research for validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cbr.2024.0220","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T04:39:52Z","timestamp":1745296792000},"page":"277-284","source":"Crossref","is-referenced-by-count":1,"title":["Anlotinib as a Tailored Treatment for Extensive-Stage Small Cell Lung Cancer with Stable Disease after Two Cycles of First Chemotherapy Plus Immunotherapy: A Retrospective Study"],"prefix":"10.1177","volume":"40","author":[{"given":"Yonghong","family":"Li","sequence":"first","affiliation":[{"name":"Department of Oncology, The First People\u2019s Hospital of Tianmen, Tianmen, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3332-0575","authenticated-orcid":false,"given":"Xiaobing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00235-0"},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.10.002"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2019.01.034"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100408"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32222-6"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01957-3"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03132-1"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.04.001"},{"issue":"8","key":"e_1_3_7_11_2","first-page":"3679","article-title":"Maintenance anlotinib improves the survival prognosis of extensive-stage small cell lung cancer: A single-arm, prospective, phase II study","volume":"13","author":"Kong F","year":"2023","unstructured":"Kong F, , Wang Z, , Wang N, et al. Maintenance anlotinib improves the survival prognosis of extensive-stage small cell lung cancer: A single-arm, prospective, phase II study. Am J Cancer Res, 2023; 13(8):3679\u20133685.","journal-title":"Am J Cancer Res"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000001488"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.655316"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0664-7"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0939-x"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3039"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2024_240716N299"},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1159"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01055"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2022.188798"},{"key":"e_1_3_7_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature14664"},{"key":"e_1_3_7_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.12.014"},{"key":"e_1_3_7_23_2","first-page":"1","article-title":"Efficacy and safety of anlotinib as maintenance therapy in patients with advanced non-small cell lung cancer achieving SD post first-line chemotherapy combined with immunotherapy","author":"Li X","year":"2024","unstructured":"Li X, , Peng Y, , Wu D, et al. Efficacy and safety of anlotinib as maintenance therapy in patients with advanced non-small cell lung cancer achieving SD post first-line chemotherapy combined with immunotherapy. J Chemother, 2024:1\u20139.","journal-title":"J Chemother"},{"key":"e_1_3_7_24_2","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2020.11685"},{"key":"e_1_3_7_25_2","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2019.1629017"},{"key":"e_1_3_7_26_2","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S426898"},{"key":"e_1_3_7_27_2","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-24-394"},{"key":"e_1_3_7_28_2","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2021-0147"},{"key":"e_1_3_7_29_2","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-22-666"},{"key":"e_1_3_7_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-024-05808-0"},{"key":"e_1_3_7_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2511-3"},{"key":"e_1_3_7_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216892"},{"key":"e_1_3_7_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112053"},{"key":"e_1_3_7_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02641-5"},{"key":"e_1_3_7_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000001481"},{"key":"e_1_3_7_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.12977"},{"key":"e_1_3_7_37_2","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S472196"},{"key":"e_1_3_7_38_2","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-23-387"},{"key":"e_1_3_7_39_2","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-23-1860"},{"key":"e_1_3_7_40_2","doi-asserted-by":"publisher","DOI":"10.3727\/096504018X15288447760357"},{"key":"e_1_3_7_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-022-01279-7"},{"key":"e_1_3_7_42_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11230-5"},{"key":"e_1_3_7_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.03.011"},{"key":"e_1_3_7_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.09.008"}],"container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cbr.2024.0220","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cbr.2024.0220","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cbr.2024.0220","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:11:37Z","timestamp":1777385497000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cbr.2024.0220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1089\/cbr.2024.0220"],"URL":"https:\/\/doi.org\/10.1089\/cbr.2024.0220","relation":{},"ISSN":["1084-9785","1557-8852"],"issn-type":[{"value":"1084-9785","type":"print"},{"value":"1557-8852","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]}}}